Rocket had $318.2 million in cash and investments as of March 31 and expects funding to last into 2027. RP-A501 trial was halted after a patient died from systemic infection and capillary leak ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

A digital therapy that could reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS ... the rate of important clinical improvement in tics ...

SAN DIEGO--(BUSINESS WIRE)--Scientist.com, the leading R&D procurement platform for the life sciences, today integrated Trial Insights™—its real‑time clinical‑trial analytics tool—into ...

In a new study, scientists combined strategies to deliver energy-disrupting gene therapy using ... "Previous attempts to use a pharmaceutical reagent against mitochondria targeted specific ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Subscribe Login Register Log out My Profile Subscriber Services Search EBLADE ENTER-TO-WIN BLADE REWARDS BLADE VAULT / REPRINTS OBITUARIES JOBS CLASSIFIEDS BLADE HOMES HOMES WEEKLY ADS EVENTS ...

Although RLT is gaining traction as a dermatological treatment for certain conditions, more clinical research ... Who should not use red light therapy? Individuals who have darker skin tones.